SYNGENE - Syngene Intl.
π’ Recent Corporate Announcements
Biocon Limited, the promoter of Syngene International, has filed a formal declaration under SEBI Takeover Regulations confirming that no shares were pledged or encumbered during the financial year ending March 31, 2026. This annual disclosure ensures transparency regarding the promoter's stake and confirms that the holding is free from any debt-related liens. The declaration covers all entities within the promoter group and persons acting in concert (PAC). For investors, this signifies financial stability at the promoter level and reduces risks associated with margin calls or forced liquidations.
- Declaration filed under Regulation 31(4) of SEBI (SAST) Regulations, 2011.
- Promoter Biocon Limited confirms zero encumbrance on Syngene shares for FY 2025-26.
- The disclosure covers the status as of the financial year end, March 31, 2026.
- Confirms that no direct or indirect pledges were made by the promoter group or PAC during the year.
Syngene International has scheduled its earnings conference call for April 30, 2026, at 2:00 PM IST to discuss Q4 and full-year FY2026 results. The management team will provide insights into the company's performance followed by an interactive Q&A session. Syngene currently serves approximately 400 global customers and operates over 3 million sq. ft of specialized facilities. This routine disclosure ensures transparency for shareholders ahead of the annual financial results.
- Earnings call scheduled for April 30, 2026, at 2:00 PM IST to discuss Q4 and FY26 performance
- Company infrastructure includes 3 million+ sq. ft of specialized research and manufacturing facilities
- Syngene's workforce consists of 8,300+ employees, including 5,700+ scientists
- The firm serves approximately 400 global customers across pharma, biotech, and specialty chemicals
Syngene International has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by KFin Technologies Limited, confirms that all dematerialization requests received between January 1, 2026, and March 31, 2026, were processed within the mandated 15-day timeframe. It also verifies that physical share certificates were mutilated and cancelled after verification. This is a standard regulatory filing ensuring the integrity of the company's shareholding records.
- Compliance certificate covers the quarter ended March 31, 2026
- Dematerialization requests were processed and confirmed within 15 days of receipt
- Physical security certificates were mutilated and cancelled after due verification by the RTA
- KFin Technologies Limited acted as the Registrar and Share Transfer Agent (RTA) for this process
Syngene International has received a favorable tax order for Assessment Year 2016-17, resulting in a sanctioned refund of βΉ43.16 crore including interest. This follows a successful Writ Petition in the Karnataka High Court and a partial appeal win at the National Faceless Appeal Centre (NFAC). The order addresses a previous tax demand of βΉ72.34 crore and the wrongful adjustment of refunds from earlier years. While the cash is yet to be received, the development will lead to a reduction in the company's contingent liabilities.
- Assessing Officer granted a refund of βΉ43.16 crore, including interest, for AY 2016-17.
- The order follows a Karnataka High Court ruling favoring the company regarding βΉ48.91 crore in previously adjusted refunds.
- The original tax demand for AY 2016-17 stood at βΉ72.34 crore prior to these successful appeals.
- The company expects a notable decrease in contingent liabilities related to this specific assessment year.
- The refund amount is currently pending receipt but has been officially processed by the tax authorities.
Syngene International has announced a major leadership transition where Siddharth Mittal, the current MD & CEO of Biocon Limited, will take over as MD & CEO of Syngene effective July 1, 2026. This follows the resignation of Peter Bains, who will step down on June 30, 2026. Furthermore, founder Kiran Mazumdar Shaw will transition from a Non-Executive to an Executive Chairperson role for a five-year term starting April 1, 2026. These changes signal a strategic consolidation of leadership within the Biocon Group, leveraging Mittal's 20+ years of experience in complex pharma segments.
- Siddharth Mittal appointed as MD & CEO for a 5-year term effective July 1, 2026.
- Kiran Mazumdar Shaw to become Executive Chairperson for 5 years starting April 1, 2026.
- Current MD & CEO Peter Bains to resign from his position on June 30, 2026.
- Incoming CEO Siddharth Mittal previously led Biocon's entry into GLP-1 therapies and generic formulations.
- The leadership changes are subject to shareholder approval as per SEBI regulations.
Syngene International has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the upcoming financial results. The window will remain closed until 48 hours after the declaration of the audited financial results for the quarter and year ending March 31, 2026. This is a standard regulatory procedure for listed Indian companies to prevent insider trading during the earnings preparation period.
- Trading window closure begins on April 1, 2026
- Closure is related to the audited financial results for Q4 and FY 2025-26
- Window to reopen 48 hours after the official announcement of financial results
- Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015
Syngene International Limited has scheduled a one-on-one virtual meeting with OrbiMed Advisors LLC on March 19, 2026. The meeting is set to take place at 11:00 AM IST and is part of the company's regular institutional investor engagement. The company has formally stated that no unpublished price-sensitive information (UPSI) will be shared during this interaction. This disclosure is in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.
- One-on-one virtual meeting scheduled with OrbiMed Advisors LLC
- Meeting date set for March 19, 2026, at 11:00 AM IST
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be disclosed
- Formal intimation submitted under SEBI Listing Obligations and Disclosure Requirements
Syngene International has received a favorable order from the National Faceless Assessment Centre regarding Assessment Year 2018-19. The authority has dropped penalty proceedings that were originally initiated in March 2023 following a disallowance of expenses worth Rs 2.78 crore. This follows a previous appellate order where the company was granted relief on the full disallowed amount. The company confirms there will be no material financial impact on its operations or activities due to this development.
- National Faceless Assessment Centre dropped penalty proceedings for AY 2018-19.
- The proceedings were related to a previous disallowance of expenses totaling Rs 2,78,45,669.
- The company had already secured relief for the full amount of Rs 2.78 crore in September 2025.
- The current order confirms no penalty, restrictions, or sanctions will be imposed on the company.
Syngene International Limited has scheduled a one-on-one virtual meeting with Alquity Investment Management on March 18, 2026, at 4:00 PM IST. This disclosure is part of the company's regular investor relations engagement under SEBI Regulation 30. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the discussion. Such meetings are standard practice for listed companies to interact with institutional investors regarding publicly available information.
- One-on-one virtual meeting scheduled with Alquity Investment Management.
- The meeting is set for March 18, 2026, at 4:00 PM IST.
- Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed.
- The notification was officially filed with BSE and NSE on March 13, 2026.
Syngene International Limited has scheduled a virtual one-on-one meeting with Multi-Act Equity Consultancy Pvt. Ltd. The meeting is slated for March 16, 2026, at 11:00 AM IST. This disclosure is a routine requirement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the session.
- One-on-one virtual meeting scheduled with Multi-Act Equity Consultancy Pvt. Ltd
- Meeting date set for March 16, 2026, at 11:00 AM IST
- Company confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed
- The notification was filed with stock exchanges on March 11, 2026
Syngene International has announced a significant restructuring of its senior management team, effective May 1, 2026. Three key executives, including the Interim Chief Commercial Officer, Chief Human Resources Officer, and Head of SynVent, will depart the company by mutual consent on April 30, 2026. To ensure continuity, the company has appointed Mr. Abhijit Zutshi, a Biocon veteran with over 20 years of experience, as the new CCO. Ms. Maninder Singh Puri, who has over 25 years of HR leadership experience, will join as the new CHRO.
- Departure of 3 senior management personnel including Interim CCO Caroline Hempstead and CHRO Andrew Webster on April 30, 2026.
- Appointment of Abhijit Zutshi as CCO, leveraging his 20+ years of commercial and global generics experience at Biocon.
- Appointment of Maninder Singh Puri as CHRO, bringing 25 years of experience from firms like Accenture and Biocon Generics.
- Dr. Kenneth Barr, Head of SynVent and Strategic Collaborations, will also be exiting the company by mutual consent.
- All leadership transitions are scheduled to be completed by May 1, 2026, to ensure organizational continuity.
Syngene International Limited has scheduled a one-on-one physical meeting with Tata Mutual Fund. The meeting is slated for February 25, 2026, at 3:15 PM IST in Bengaluru. This disclosure is a routine filing under Regulation 30 of SEBI Listing Obligations. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during this interaction.
- One-on-one physical meeting scheduled with Tata MF on February 25, 2026
- Meeting venue is set for Bengaluru at 3:15 PM IST
- Compliance filing under Regulation 30 of SEBI (LODR) Regulations, 2015
- Company confirmed that no unpublished price sensitive information will be disclosed
Syngene International has received favorable orders from the National Faceless Appeal Centre (NFAC) regarding tax appeals for the assessment years 2015-16, 2018-19, and 2021-22. The NFAC has partially allowed relief to the company against previous tax additions and disallowances. Consequently, the company expects a reduction in its contingent liabilities and is likely eligible for tax refunds. No penalties or sanctions have been imposed, and the company does not foresee any material negative impact on its operations.
- NFAC passed orders for AY 2015-16, 2018-19, and 2021-22, partially allowing the company's appeals against previous tax disallowances.
- The company expects a reduction in contingent liabilities and eligibility for tax refunds following these orders.
- No penalties, restrictions, or sanctions were imposed by the authority in the orders received in February 2026.
- The Assessing Officer will now pass a consequential order to give effect to the NFAC's decision.
Syngene International has received orders from the National Faceless Appeal Centre (NFAC) regarding tax disputes for three assessment years: 2013-14, 2014-15, and 2017-18. The NFAC has partially allowed the company's appeals against previous tax additions and disallowances made by the Assessing Officer. Consequently, the company expects a reduction in its contingent liabilities and is now eligible for a tax refund. While the exact monetary impact is yet to be quantified by the Assessing Officer, the management does not expect any material negative impact on financials.
- NFAC passed orders on February 13, 2026, partially allowing appeals for AY 2013-14, 2014-15, and 2017-18.
- The company expects a reduction in contingent liabilities following the favorable ruling.
- Syngene is now eligible for a tax refund once the Assessing Officer passes the final order giving effect to the NFAC ruling.
- No penalties, restrictions, or sanctions were imposed in the current orders.
Syngene International has received orders from the National Faceless Appeal Centre (NFAC) regarding tax appeals for Assessment Years 2013-14, 2014-15, and 2017-18. The NFAC has partially allowed the company's appeals against previous tax additions and disallowances made by the Assessing Officer. This outcome is expected to result in a reduction of the company's contingent liabilities and eligibility for tax refunds. While the company states there is no material impact on current financials, the resolution of these long-standing disputes provides better financial clarity.
- NFAC orders dated February 13, 2026, provide partial relief for AY 2013-14, 2014-15, and 2017-18
- Company expects a reduction in contingent liabilities and is now eligible for tax refunds
- The Assessing Officer is required to pass a final order to give effect to the NFAC's decision
- No penalties, restrictions, or sanctions were imposed on the company in these proceedings
Financial Performance
Revenue Growth by Segment
Research Services contributed 61% of total revenue in FY25 and remained stable, while Large Molecule Development and Manufacturing grew 22% YoY, increasing its revenue share from 21% in FY24 to 25% in FY25. Discovery Services saw slower growth due to a challenging US Biotech funding environment.
Geographic Revenue Split
98% of total revenues are derived from overseas markets, with the US market alone accounting for 61% of FY25 revenues. Other key regions include Europe and Japan.
Profitability Margins
Reported PAT margin for Q2 FY26 was 7% (INR 67 Cr), a significant decline from the previous year. FY25 PAT before exceptional items was INR 474.9 Cr, down 8% YoY from INR 518.6 Cr in FY24.
EBITDA Margin
Operating EBITDA margin for H1 FY26 stood at 23%, down from 25% in H1 FY25. FY25 EBITDA margin was 28.6% (INR 1,113.6 Cr) compared to 29.1% in FY24.
Capital Expenditure
Annual organic capex is planned at INR 500-600 Cr. Q2 FY26 capex was $10 million (approx. INR 84 Cr), with 50% allocated to research services (DMPK automation, ADC labs) and 30% to CDMO facilities in Bangalore and the US.
Credit Rating & Borrowing
ICRA reaffirmed [ICRA]AA+ (Stable) for long-term ratings and [ICRA]A1+ for short-term facilities totaling INR 1,500 Cr. Adjusted gearing is exceptionally low at 0.03 times as of March 31, 2025.
Operational Drivers
Raw Materials
Costs of chemicals, reagents, and consumables consumed represented 26.2% of revenue in Q2 FY26, totaling INR 238.5 Cr.
Import Sources
Not explicitly disclosed by country, but the company is developing a diversified supplier network to reduce dependency on high-cost suppliers.
Capacity Expansion
Acquired a Biologics manufacturing facility in Baltimore, USA (operational by Dec 2025) and another facility (Stelis Unit 3) in Bangalore to drive Large Molecule growth.
Raw Material Costs
Raw material costs in FY25 were INR 942.5 Cr, a 1% increase YoY. The company expects full-year raw material costs to stabilize around 25% of revenue.
Manufacturing Efficiency
Focus on 'level of productivity' to match 'China switcher' expectations; utilizing AI tools for process simplification and delivery turnaround time.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Achieving growth through the '1-3-5 plan' focusing on Large Molecule CDMO, operationalizing the Baltimore facility by Dec 2025, and expanding SynVent Integrated Drug Discovery (IDD) services. The company is also targeting 'China switchers'βclients moving supply chains away from China.
Products & Services
Contract research (CRO), discovery services (DMPK, ADC labs), biologics manufacturing (Large Molecule CDMO), small molecule CDMO, and payload/linker manufacturing.
Brand Portfolio
Syngene, SynVent, SynVent IDD.
New Products/Services
New capabilities in Antibody-Drug Conjugates (ADC) labs and payload/linker manufacturing to complement existing commercial capabilities.
Market Expansion
Expanding commercial teams closer to client locations in North America, Europe, and Japan; new manufacturing presence in Baltimore, USA.
Market Share & Ranking
Not disclosed in percentage terms, but noted as a leading player in the Indian contract research space.
Strategic Alliances
Maintains dedicated research centers for major clients and strategic marketing focused on high-value key account management.
External Factors
Industry Trends
The industry is shifting toward Large Molecule/Biologics CDMO; Syngene is positioning itself by increasing Biologics revenue share to 25%.
Competitive Landscape
Faces competition from global CROs, domestic players, and captive R&D centers of large pharma companies.
Competitive Moat
Moat built on high-end scientific talent, robust compliance/safety records (EcoVadis score 74/100), and long-term integrated contracts that create high switching costs.
Macro Economic Sensitivity
Highly sensitive to US Biotech funding cycles and global pharmaceutical R&D spending trends.
Consumer Behavior
Increased preference for 'one-stop-shop' providers that can handle both discovery and commercial-scale manufacturing.
Geopolitical Risks
Exposure to US-China trade shifts (China switchers) provides an opportunity, while 61% revenue concentration in the US poses a geographic risk.
Regulatory & Governance
Industry Regulations
Strict adherence to pharma regulatory approvals and clinical trial regulations; implementing digital tracking for licenses and permits.
Environmental Compliance
Earned 'Green Certification' from My Green Lab with a score >94%; EcoVadis 2025 score rose to 74/100 (91st percentile).
Taxation Policy Impact
Tax expense increased 35% YoY to INR 153 Cr in FY25. The company adopts a litigation strategy for ongoing tax cases with expert advisors.
Legal Contingencies
Ongoing tax disputes and contractual management risks are monitored by an executive-level committee; specific INR values for pending litigations not disclosed.
Risk Analysis
Key Uncertainties
Inability to match productivity expectations of 'China switchers' and potential delays in obtaining pharma regulatory approvals for new facilities.
Geographic Concentration Risk
61% of revenue is concentrated in the US market.
Third Party Dependencies
Significant dependency on top 2 clients (41% of revenue) and Biocon (parent company support).
Technology Obsolescence Risk
Mitigated by investments in AI tools, DMPK automation, and digitization of laboratory processes.
Credit & Counterparty Risk
Strong liquidity with INR 1,398 Cr in liquid surplus and cash accruals of over INR 850 Cr in FY25.